This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Legal Team Sues Drug Maker Hoffmann-La Roche Limited Over Popular Acne Medicine

LONDON, ON, Feb. 4, 2013 /CNW/ - When Jennifer Twamley was prescribed Accutane at 17 to control her acne, little did she know the long-term impact the drug would have on her life.

Twamley, 33, now suffers from Ulcerative Colitis, an inflammatory bowel disease (IBD), which lawyers Barb Legate of Legate & Associates and Dave Williams of Harrison Pensa say is a side effect of Accutane.

Twamley has undergone two surgeries, including removal of her colon. "It's been devastating," says Twamley, whose career and lifestyle have been drastically curtailed. "I wish I had never taken that drug. Having a chronic illness is isolating."

Twamley, a television producer, is suing drug maker Hoffmann-La Roche over Accutane in what is known as a mass tort, one of the first in Canada involving the acne drug. The lawsuit was filed in the Ontario Superior Court of Justice.

A mass tort is a group of lawsuits involving individuals who share similar complaints as a result of their experiences with a drug or defective product. Mass torts are common in the United States, where Roche has already been successfully sued for millions of dollars in connection with the manufacture and sale of Accutane.  Roche stopped selling Accutane in the United States in 2009 for business reasons, but the drug is still sold in Canada.

Legate says Accutane has destructive side effects that many Canadians weren't warned about. "We believe there are thousands of victims in Canada who have been hurt by Accutane. We are seeking justice for them." Williams adds, "Studies in the U.S. have found that Accutane is linked to inflammatory bowel disease, which includes Ulcerative Colitis and Crohn's disease."

"The sad thing is that many people who have developed a disease like colitis or Crohn's don't realize that a common drug they were prescribed as a teenager for their acne could be the likely cause. It has had harsh consequences," he added.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs